Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-04-28 07:00:23
Tromsø, Norway, 28[th] April 2022 - ArcticZymes Technologies (OSE: AZT) reported
sales of NOK 49.2 million (40.9) and an EBITDA of NOK 27.9 million (25.8) for
the first quarter of 2022.
Highlights from Q1 2022
· ArcticZymes Technologies (AZT) had Q1 sales of NOK 49.2 million growing by
21% (Q1 2021: NOK 40.9 million)
· Positive EBITDA of NOK 27.9 million (Q1 2021: NOK 25.8 million)
· Cash flow for Q1 was positive NOK 14.2 million (Q1 2021: NOK 23.2 million)
giving a cash balance of NOK 214.6 million (Q1 2021: NOK 163.3 million)
· Signed a new OEM supply deal with a leading global Life Science company
· Established new application laboratory at ShareLab in Oslo
CEO Jethro Holter comments:
"We are delighted with the strong performance of our first quarter for 2022. The
ArcticZymes team has delivered the best-ever quarterly performance achieving
sales revenues of NOK 49.2 million and an EBITDA of NOK 27.9 million. Both
Molecular Tools and Biomanufacturing were instrumental in delivering growth.
Furthermore, ArcticZymes is proud to expand its operational activities outside
of Tromsø and strategically establish itself at ShareLab in Oslo. Initial
activities at Sharelab will focus on application development."
-Ends-
First Quarter 2022 Presentation and Webcast
The Company will host a presentation for investors, analysts and media at 08:30
CET on Thursday, 28[th] April 2022 at Hotel Continental, Stortingsgata 24/26,
Oslo.
The presentation will be given by CEO, Jethro Holter and CFO, Børge Sørvoll
The presentation can also be followed as a live webcast from Hegnar TV on
www.arcticzymes.com or
https://channel.royalcast.com/landingpage/hegnarmedia/20220428_14/. It will be
possible to post questions through the webcast console.
The results, report and presentation for the first quarter 2022 will be
available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company's
homepage www.arcticzymes.com from 07:00 CET on 28[th] April 2022.
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com